drug

Pfizer ends development of "blockbuster" cholesterol drug after excessive patient deaths

Monday, December 11, 2006 by: Jessica Fraser
Tags: Pfizer, cholesterol drugs, drug trials

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
CDC issues flu vaccine apology: this year's vaccine doesn't work!
The five biggest lies about Ebola being pushed by government and mass media
Why does the CDC own a patent on Ebola 'invention?'
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
Tetanus vaccines found spiked with sterilization chemical to carry out race-based genocide against Africans
Oregon man serving prison sentence for collecting rainwater on his own property
Russia taking McDonald's to court, threatens countrywide shutdown
Global warming data FAKED by government to fit climate change fictions
The best way to help your body protect itself against Ebola (or any virus or bacteria)
Healthy 12-year-old girl dies shortly after receiving HPV vaccine
Ebola outbreak may already be uncontrollable; Monsanto invests in Ebola treatment drug company as pandemic spreads
HOAX confirmed: Michelle Obama 'GMOs for children' campaign a parody of modern agricultural politics
Ben & Jerry's switches to non-GMO, Fair Trade ice cream ingredients
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces
BREAKING: CDC whistleblower confesses to MMR vaccine research fraud in historic public statement
Monsanto's seed imperialism halted in Canada thanks to massive protests
Cannabis dissolves cancerous tumor in young infant, deemed a 'miracle baby' by physician
Top ten things you need to do NOW to protect yourself from an uncontrolled Ebola outbreak

Delicious
(NaturalNews) Pharmaceutical giant Pfizer announced that it has ended a clinical trial for the highly anticipated cholesterol drug torcetrapib -- which raises levels of "healthy" HDL cholesterol -- after a high number of patients participating in the trial died or experienced cardiovascular problems.

Pfizer, the world's largest drug firm, was informed over the weekend that an independent board monitoring a study of torcetrapib found that 82 patients out of 7,500 who were taking the drug had died. Fifty-one patients out of 7,500 in the same study who were taking Lipitor -- Pfizer's best-selling cholesterol drug -- also died, though the company said it was not concerned over Lipitor's safety.

According to Pfizer spokesman Paul Fitzhenry, the company is requesting that all clinical investigations of torcetrapib be halted, and patients taking the drug stop immediately. Previous studies had shown the drug to slightly increase blood pressure, but researchers were unclear on whether high blood pressure contributed to the patients' deaths or heart troubles.

Pfizer -- which spent roughly $800 million on the development of torcetrapib -- was counting on the success of the drug to invigorate slow sales. Several patent expirations are projected to cost the company $14 billion in annual sales between 2005 and 2007, and its patent on the world's best-selling drug, Lipitor, could expire by 2010.

Pharmaceutical industry critics say Pfizer's decision can be credited largely to more intense scrutiny of the safety of clinical trials following Merck's withdrawal of the painkiller Vioxx from the market in late 2004.

Consumer health advocate Mike Adams, author of "The Seven Laws of Nutrition," called Pfizer's decision to halt trials of torcetrapib a "tremendous victory" for the health and safety of patients around the world.

"I believe this decision would never have been reached without the increased scrutiny now being directed at Big Pharma," Adams said. "In my opinion, if this drug had been developed five years ago, the trial results would have been tweaked to make it appear safer, and the drug would have been released anyway."

Members of the committee that oversaw the study said they were surprised to discover the increased death rates, since earlier study results had been promising. However, Adams says the decision to abandon testing of torcetrapib -- which was made prior to FDA evaluation of the drug -- averted possible disaster in light of the FDA's shoddy track record of approving unsafe drugs.

"Pfizer announced just two days before this decision that it was seeking FDA approval for the drug," Adams said. "No one in their right mind should believe that the FDA would have denied approval for this drug, especially while the agency continues to support Vioxx, a drug that has killed more than 50,000 Americans."

In spite of the loss of projected "blockbuster" torcetrapib, Pfizer emphasized at a recent analyst meeting that it still has 242 research programs and other drugs in the pipeline.

###

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.